BCP Partnering Portal / ViraCoat
A subsidiary of ViraCorp, ViraCoat has developed a novel Virucidal, Antiviral & Antimicrobial Coating which has been demonstrated to have profound antiviral properties against SARS-CoV-2 (including new strains), Influenza (PR8 strain), and Bacteria (E. coli).
This proprietary Coating can be applied to and incorporated into PPE and other products to inactivate the virus and help to reduce the spread of COVID-19 and other infectious diseases.
A more effective solution for Personal Protective Equipment with more efficacy, less waste, and less spend.
ViraCoat’s Antiviral & Antimicrobial Coating can be applied to and incorporated into PPE and other products to inactivate the virus and help reduce the spread of COVID-19 and other pathogens to an efficacy rate of 90% within 5 minutes and 100% within 30 minutes.
COVID-eliminating & virucidal FFP2 Face MaskViraCoat’s Neutrapodal™ Technology has been incorporated into the ViraCoat COVID-eliminating Virucidal FFP2 Mask at a manufacturing level, to inactivate the virus and help reduce the spread of COVID-19 and other bacteria to an efficacy of 99.9% within 5 minutes of contact.*With stringent, comprehensive safety R&D and approvals, our next-generation FFP2 Mask has been scientifically demonstrated to have profound antiviral properties against SARS-CoV-2 (including new strains), Influenza (PR8 strain), and Bacteria (E. coli).